Investors

Corporate Profile

Rigel Pharmaceuticals, Inc. is a biotechnology company dedicated to discovering, developing and providing novel, small molecule drugs that significantly improve the lives of patients with immune and hematological disorders, cancer and rare diseases.
 

Corporate Investor Presentation

Rigel Corporate Investor Presentation

More »
Recent News
DateTitle 
03/26/19
Peter S. Ringrose, Ph.D. Retires from Board Position SOUTH SAN FRANCISCO, Calif. , March 26, 2019 /PRNewswire/ -- Rigel Pharmaceuticals , Inc. (Nasdaq: RIGL) today announced that it has appointed Jane Wasman to its board of directors. Ms. Wasman is a strategic leader with over 20 years of
02/28/19
Fourth quarter total revenues of $37.9 million; full year total revenues of $44.5 million Fourth quarter net product sales of $7.3 million; full year net product sales of $13.9 million Conference call and webcast today at 5:00PM Eastern Time SOUTH SAN FRANCISCO, Calif. , Feb.
02/21/19
SOUTH SAN FRANCISCO, Calif. , Feb. 21, 2019 /PRNewswire/ --  Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its fourth quarter and year end 2018 financial results after market close on Thursday, February 28 , 2019.  Rigel senior management will follow the announcement

Stock Quote

(Common Stock)
Exchange (US Dollar)
Price
Change (%)
Volume
Data as of
More »
Upcoming Events
More events are coming soon.
What's New

E-mail Alerts

Click here to receive e-mail alerts whenever Rigel Pharmaceuticals Inc. posts new information to the site